Work

Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz255.026

Authors: C. Robert, D. Schadendorf, R. Dummer, K.T. Flaherty, H.A. Tawbi, A.M. Menzies, A. D’Amelio, E. de Jong, E. Gasal, G.V. Long

Institutions: Université Paris-Sud, Institut Gustave Roussy, Fondation Gustave Roussy, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University Hospital Zurich, Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, The University of Sydney, Melanoma Institute Australia, Novartis (Switzerland), Novartis (United States)

Language: French

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Sanofi, Celgene, Array BioPharma, Aeglea BioTherapeutics, Les Laboratories Pierre Fabre, Incyte, Genentech

OpenAlex ID: W2978778656

FWCI: 0.072

Cites:

Cited by: 1

Related to: 10